

INDUSTRY NEWS IN BRIEF

iScience launches support Web site for canaloplasty surgeons

MENLO PARK, Calif. — iScience International has launched a new surgeon support Web site to help ophthalmic surgeons adopt the canaloplasty procedure into their practices, the company announced in a press release. Open to all registered canaloplasty-

trained physicians who have integrated the procedure into their surgical regimens, the new site, called iForum, features a peer-to-peer chat room, message board, webinars and procedure video footage. Users can access clinical materials and resources on the latest advances and educational tools for canaloplasty, as well as downloadable educational seminars, presentations

and a surgical technique video gallery, the release said.

To coincide with the launch of the site, iScience has sent an introductory e-mail with access information to all registered canaloplasty-trained surgeons. For more details, visit iforum-md.com.

HyperBranch licenses OcuSeal liquid ocular bandages to BD Medical

DURHAM, N.C. — HyperBranch Medical Technology has licensed its OcuSeal liquid ocular bandages to BD, HyperBranch announced in a press release.

Under the license, BD subsidiary BD Medical – Ophthalmic Systems will retain exclusive global rights to market OcuSeal ocular bandages for ophthalmic indications. BD Medical plans to begin international commercialization of the product immediately, the release said.

HyperBranch has been marketing and selling OcuSeal liquid ocular bandages through independent distributors since receiving a CE Mark in 2007.

“OcuSeal is a significant improvement for a variety of ophthalmic procedures, and BD is an excellent partner to offer this technology to a wider

market,” John Conn, president and chief executive officer of HyperBranch, said in the release. “The transaction with an industry leader like BD further validates our platform technology and in a very sensitive field of use.”

FDA accepts for review Sirion's supplemental new drug application for Durezol

TAMPA, Fla. — Sirion Therapeutics' supplemental new drug application for a topical corticosteroid for treating endogenous anterior uveitis has been accepted for review by the U.S. Food and Drug Administration, the company announced in a press release.

The supplemental application includes data compiled from three clinical studies, including a recently completed U.S. trial and two phase 3 studies conducted by Senju Pharmaceutical in Japan, the release said. Currently, FDA protocol stipulates that clinical trials of all potential uveitis treatments must be tested against existing standard treatment and cannot be tested against placebo.

In the U.S. trial, which compared a four times daily dosing regimen of

SEND YOUR PATIENTS HOME IN TEARS.



OPHTHALMIC STOCK NEWS

90-Day Stock Trends

AGM, GM, DTG, INO, A, H, R, N, C, Q, W, J, M, O, S, Y, A, M, I, T, H, S, H, M